And although shares fell 35% from peak-to-trough, it became apparent that those who seek these weight-loss drugs also tend to ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...